Lyme disease (LD) is caused by Borrelia burgdorferi, a diderm bacteria transmitted via regurgitated saliva of bites of infected ticks. It usually presents as flu-like syndrome, however the classical erythema migrans (EM) rash is often missed or unrecognized. If not treated definitively during early infection, patients can suffer severe and often irreversible consequences including facial palsy, polyarthritis, neuropathy and carditis. The prevalence of LD has increased exponentially over the past 40 years due to the inexorable spread of infected ticks across the US. More than 3 million Lyme tests are performed annually. Surprisingly, in contrast to other bacterial infections, direct detection of LD bacterium genomic materials and antigens are not particularly useful in early diagnosis. This is due to the extreme scarcity of LD bacteria in the circulation. The two-tier serological testing algorithm (first-tier enzyme immunoassay followed by a second-tier Western blot) is still the mainstay of Lyme testing. However, the two-tier algorithm identifies less than 40% of early infected LD, signaling an urgent and compelling need for better diagnostics for early detection of LD.
Enable Biosciences has developed a highly sensitive and specific multiplex Lyme and tick-borne disease immunoassay. The enhanced sensitivity of the assay has the potential to improve diagnosis during the early stage of disease to permit effective treatment.
This product is RESEARCH USE ONLY. Contact us for more information at firstname.lastname@example.org
Lyme disease (LD) is caused by the bacterium Borrelia burgdorferi transmitted to humans through the bite of infected blacklegged ticks.
Typical symptoms include fever, headache, fatigue and a skin rash called erythema migrans, is often missed or unrecognized.
If the infection is not recognized and treated properly during the early stages, patients can suffer severe and often irreversible consequences including facial palsy, polyarthritis, neuropathy and carditis.
Over the past 40 years the prevalence of LD has increased dramatically, due to the inexorable spread of infected ticks across the US.
More than 3 million Lyme tests are performed every year.
Unfortunately, the Two-tier (first-tier enzyme immunoassay followed by a second-tier Western blot) serological testing algorithm is able to identify less than 40% of early infected LD.
Stanek G, Wormser GP, Gray J, Strle F. Lyme borreliosis. Lancet 379(9814):461-73 (2012).
Hinckley AF, et. al. Lyme disease testing by large commercial laboratories in the United States. Clin Infect 59(5):676-81 (2014).
Waddell LA, et. al. The accuracy of diagnostic tests for lyme disease in humans, a systematic review and meta-analysis of north American research. PLoS One. 11(12): e0168613 (2016).
Tsai CT, et. al. Antibody detection by agglutination-PCR (ADAP) enables early diagnosis of HIV infection by oral fluid analysis. Proc Natl Acad Sci U S A. 115(6):1250-1255 (2018).
Tsai CT, Robinson PV, Spencer CA, Bertozzi CR. Ultrasensitive antibody detection by agglutination-PCR (ADAP). ACS Cent Sci. 2(3):139-147 (2016).